Full Press Release Details
Investor Relations | Corporate Communications | Clinical Trial Patient Recruitment
AI Announces Three - Year Global Strategic Partnership with
Lieber Institute for Brain Development
Strategic Collaboration will Leverage Bullfrog AI's bfLEAP AI Platform to Accelerate R&D Initiatives, Including New
Drug Target And Disease Biomarker Identification
MD - September 13, 2023 - BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("BullFrog AI" or the
"Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable
the successful development of pharmaceuticals and biologics, today announced a three-year global strategic partnership with the Lieber
Institute for Brain Development (LIBD), a non-profit research institute that maintains the world's largest repository of postmortem
brains for the study of neuropsychiatric disorders.
the terms of the agreement, BullFrog AI will leverage its bfLEAP platform to mine LIBD's comprehensive brain data, including
transcriptomic, genomic, DNA methylation, cell-line, clinical, and imaging data. The goal of the partnership is to identify previously
unrecognized relationships between genes and pathways in the brain and the development of neurologic and psychiatric disorders, thereby
facilitating the development of more effective treatments for diseases of the human brain. The collaboration will proceed in two stages,
with the first involving unsupervised construction of graphical models to reveal relationships between brain diseases and genomic/biologic
attributes, with the goal of identifying new biomarkers and drug targets across disorders. The second stage will involve creating disease-specific
models that will enable identification of genes and pathways within these respective disorders.
first of its kind global partnership with LIBD represents a significant advancement in using AI to drive precision medicine and will
leverage BullFrog AI's bfLEAP artificial intelligence platform to accelerate research and development initiatives, including
drug repurposing, clinical trial optimization, and drug target identification," said Vin Singh, CEO of BullFrog AI. "Access
to best-in-class data is a critical first step in harnessing AI to improve drug development. Combining our proprietary bfLEAP
artificial intelligence platform with LIBD's extensive brain-related data positions us to accelerate the development of therapies
for psychiatric and neurologic disorders."
partnership includes a one-year term of data exclusivity to complete the first stages of analyses, with a two-year extension option as
performance milestones are met. Throughout the collaboration, BullFrog AI will receive access to LIBD's collection of brain data
for further analyses and additional research projects. BullFrog AI will also have the right to commercialize any product or service generated
from the data. The agreement specifies sharing of revenue between BullFrog AI and LIBD from products or services generated from the partnership.
partnership enables us to apply BullFrog AI's innovative AI platform to rapidly accelerate our research and development initiatives,"
said Daniel R. Weinberger, M.D., Director and CEO of LIBD. "We strongly believe this collaboration will advance our understanding
of brain disorders and ultimately lead to new and better treatments for psychiatric and neurologic diseases."
W. 35th Street, 11th Floor | New York, NY 10001 | 212 827 0020 | www.tiberend.com
Investor Relations | Corporate Communications | Clinical Trial Patient Recruitment
the Lieber Institute for Brain Development (LIBD)
mission of the Lieber Institute for Brain Development and the Maltz Research Laboratories is to translate the understanding of
basic genetic and molecular mechanisms of schizophrenia and related developmental brain disorders into clinical advances that change
the lives of affected individuals. LIBD is an independent, not-for-profit 501(c)(3) organization and a Maryland tax-exempt medical research
institute. The Lieber Institute's brain repository of more than 4,000 human brains is the largest collection of postmortem brains
for the study of neuropsychiatric disorders in the world.
AI is a technology-enabled drug development company that creates and analyzes networks of biological, clinical, and real-world data spanning
from early discovery to late-stage clinical trials. Through its partnerships with leading research institutions, BullFrog AI is at the
forefront of AI-driven drug development using its proprietary bfLEAP artificial intelligence platform. BullFrog AI is deploying
bfLEAP for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development,
decreasing the overall development costs by decreasing failure rates for new therapeutics.
more information visit BullFrog AI at
W. 35th Street, 11th Floor | New York, NY 10001 | 212 827 0020 | www.tiberend.com
Investor Relations | Corporate Communications | Clinical Trial Patient Recruitment
press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about
future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events
or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business
prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those
that use terminology such as "may," "should," "expects," "anticipates," "contemplates,"
"estimates," "believes," "plans," "projected," "predicts," "potential,"
or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider
various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing
market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially
from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press
release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ
materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking
statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other
statements made from time to time by us or our representatives might not occur.
RedChip Companies, Inc.
Strategic Advisors, Inc.
BullFrog AI Holdings, Inc.
W. 35th Street, 11th Floor | New York, NY 10001 | 212 827 0020 | www.tiberend.com